You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
| Title |
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial
|
|---|---|
| Published in |
Trials, May 2022
|
| DOI | 10.1186/s13063-022-06370-1 |
| Pubmed ID | |
| Authors |
Nicholas A. Turner, Smitha Zaharoff, Heather King, Scott Evans, Toshimitsu Hamasaki, Thomas Lodise, Varduhi Ghazaryan, Tatiana Beresnev, Todd Riccobene, Rinal Patel, Sarah B. Doernberg, Urania Rappo, Vance G. Fowler, Thomas L. Holland |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 40% |
| Spain | 2 | 13% |
| Israel | 1 | 7% |
| Unknown | 6 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 73% |
| Practitioners (doctors, other healthcare professionals) | 2 | 13% |
| Scientists | 2 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 5 | 17% |
| Student > Bachelor | 5 | 17% |
| Student > Ph. D. Student | 2 | 7% |
| Student > Master | 2 | 7% |
| Student > Doctoral Student | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 12 | 41% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 5 | 17% |
| Medicine and Dentistry | 5 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
| Nursing and Health Professions | 2 | 7% |
| Immunology and Microbiology | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 13 | 45% |